top of page

Rafarma Pharmaceuticals has developed a non-hardening gel for the radiopharmaceutical market

Rafarma Pharmaceuticals, Inc. (OTC: RAFA) has created a promising for the pharmaceutical industry prototype gel base. A substance doesn't contain potentially toxic components and can be used to produce radiopharmaceuticals based on it. The group of companies is working on intellectual property patenting at the moment.

Topical preparations have been in the company's field of interest for a long time. The company has been conducting research and clinical trials on a new preparation for radiosynovectomy (RSV) for several years. The procedure for chronic inflammatory diseases of the joint’s treatment consists of the intra-articular injection of a radioactive substance that affects the synovial membrane.

According to a similar effect principle, a promising gel will potentially allow treatment and remove inaccessible surgical intervention tumours and metastases. It is especially true for inflammation located in critical human tissues and organs.

Preliminary tests of the properties of the substance at different temperatures (4°C - 6°C and 30°C - 37°C, max 42°C) confirmed its suitability for the medical purposes:

  • At low temperature, the prototype has the form of a liquid of low or medium viscosity, passes through the injection needle without significant resistance

  • At above 28°C - 30°C, the base takes the solid form

To date, the company has already conducted a study of the material for resistance to ionizing radiation and radiolysis of a substance in a gamma sterilization unit. The substance's basic physical properties have not changed, and the tests were considered successful. Furthermore, in three weeks, Rafarma Pharmaceuticals will receive new data on the gel and its potential in radiopharmaceuticals. During this time, the contractor's laboratory will be able to issue the first conclusions in the course of its observation of the sample with a sample of Y-90 microspheres (> 20 GBq) introduced into it.

Rafarma Pharmaceuticals plans to continue to conduct research and laboratory testing, setting itself the goal of registering on the international market a radiopharmaceutical based on gel and yttrium microspheres, commercially produced by Bebig LLC.


Rafarma Pharmaceuticals is an international holding company engaged in projects conducting the production and market entry of innovative drugs and technology platforms. The business has had a reputation as a reliable manufacturer and distributor since 1930. Rafarma Pharmaceuticals run more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging and many other fields at the moment.

For more information, please visit


Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.



(307) 429-2029

Source: Rafarma Pharmaceuticals, Inc.


bottom of page